Proximus plc (PROX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Proximus plc (Proximus) is a provider of connectivity and digital services. The company is involved in the operation of open fixed and mobile networks, the development of digital ecosystems, and the provision of innovative solutions. Proximus offers a range of services, including fixed and mobile telephony, internet, and television services. The company provides services under several brands, such as Proximus, Scarlet, Mobile Vikings, Route Mobile, Telesign, BICS, Tango, and Doktr. It serves retail, industrial and commercial customers. The company has business presence in Luxembourg, France, Germany, the US, Singapore, Italy, Spain, the Netherlands and the UK. Proximus Group is headquartered in Brussels, Belgium.
Proximus plc Key Recent Developments
Jun 06, 2026: Proximus Activates Three 5G Slices at Red Devils Farewell Match
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
UCB SA - Key Facts
UCB SA - Key Employees
UCB SA - Key Employee Biographies
UCB SA - Major Products and Services
UCB SA - History
UCB SA - Company Statement
UCB SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 - Company Analysis
Company Overview
UCB SA - Business Description
Product Category: Established Brands
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Neurology
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: Japan
Performance
Geographical Segment: U.S.
Performance
R&D Overview
UCB SA - Corporate Strategy
UCB SA - SWOT Analysis
SWOT Analysis - Overview
UCB SA - Strengths
UCB SA - Weaknesses
UCB SA - Opportunities
UCB SA - Threats
UCB SA - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
UCB SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
Jun 17, 2026: UCB Publishes Brain Communications Data Showing KYGEVVI Improves Outcomes in Patients With Thymidine Kinase 2 Deficiency (TK2d)
Jun 12, 2026: Reflections from EULAR 2026: advancing early control of inflammation
Jun 02, 2026: UCB Presents Research at Euromit 2026 Highlighting Burden of Care, Need for Earlier Diagnosis, and Impact of Pyrimidine Nucleoside Therapy on People Living With Tk2d
Jun 01, 2026: UCB Launches Scholarship Program for Adults With Hidradenitis Suppurativa and Immediate Family Members
May 21, 2026: FASTRAX Canada Expands to Québec City, Strengthening National Efforts to Accelerate AxSpA Diagnosis
May 07, 2026: UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
May 07, 2026: UCB : Celebrating a decade of partnership advancing digital innovation in epilepsy care
Mar 25, 2026: UCB banks on Georgia for $2bn biologics manufacturing facility
Mar 24, 2026: UCB Selects Rowen for $2B Biopharmaceutical Manufacturing Campus
Feb 26, 2026: UCB Announces Full-Year Report 2025
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
UCB SA, Key Facts
UCB SA, Key Employees
UCB SA, Key Employee Biographies
UCB SA, Major Products and Services
UCB SA, History
UCB SA, Subsidiaries
UCB SA, Joint Venture
UCB SA, Key Competitors
UCB SA, Ratios based on current share price
UCB SA, Annual Ratios
UCB SA, Interim Ratios
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
UCB SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
UCB SA, Performance Chart (2021 - 2025)
UCB SA, Ratio Charts
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net